animal models and interpreting research results.

3. Publishing research results.

The role of the CRADA Collaborator may include, but not be limited to:

1. Providing significant intellectual, scientific, and technical expertise or experience to the research project.

2. Planning research studies and interpreting research results.

3. Providing samples of the subject compounds to test, optimize and develop for their anti-angiogenic and anti-tumor potential.

4. Providing technical and/or financial support to facilitate scientific goals and for further design of applications of the technology outlined in the agreement.

5. Publishing research results.

Selection criteria for choosing the CRADA Collaborator may include, but not be limited to:

1. The ability to collaborate with NCI on the research and development of this technology. This ability can be demonstrated through experience and expertise in this or related areas of technology indicating the ability to contribute intellectually to ongoing research and development.

2. The demonstration of adequate resources to perform the research and development of this technology (e.g. facilities, personnel and expertise) and accomplish objectives according to an appropriate timetable to be outlined in the CRADA Collaborator's proposal.

3. the willingness to commit best effort and demonstrated resources to the research and development of this technology, as outlined in the CRADA Collaborator's proposal.

4. The demonstration of expertise in the commercial development and production of products related to this area of technology.

5. The level of financial support the CRADA Collaborator will provide for CRADA-related Government activities.

6. The willingness to cooperate with the National Cancer Institute in the timely publication of research results.

7. The agreement to be bound by the appropriate DHHS regulations relating to human subjects, and all PHS policies relating to the use and care of laboratory animals.

8. The willingness to accept the legal provisions and language of the CRADA with only minor modifications, if any. These provisions govern the distribution of patent rights to CRADA inventions. Generally, the rights of ownership are retained by the organization that is the employer of the inventor, with (1) the grant of a license for research and other Government purposes to the Government when the CRADA Collaborator's employee is the sole inventor, or (2) the grant of an option to elect an exclusive or nonexclusive license to the CRADA Collaborator when the Government employee is the sole inventor.

Dated: September 4, 1998.

Kathleen Sybert,

Acting Director, Office of Technology Development, National Cancer Institute, National Institutes of Health.

[FR Doc. 98–24810 Filed 9–11–98; 3:08 pm]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of Alternative Medicine, Office of the Director; Notice of Meeting

Pursuant to Pub. L.92–463, notice is hereby given of the meeting of the Alternative Medicine Program Advisory Council on September 24–25, 1998 at the Doubletree Hotel, 1750 Rockville Pike, Rockville, Maryland.

The two-day meeting will be open to the public from 8:30 to 4:30 p.m. on September 24 and 8:30 a.m. to adjournment on September 25, 1998. Attendance by the public will be limited to space available. The purpose of the meeting will be to update and review the progress of the Office of Alternative Medicine and obtain Council's advice on research activities. Additional agenda items include: (1) a report on current AM initiatives; (2) future AM initiatives; (3) AM Cancer trials; and (4) other business of the Council.

A public comment session is scheduled for September 25 from 10:15 a.m. to 11:15 a.m. Only one representative of an organization may present oral comments. Each speaker will be permitted 5 minutes for their presentation. Interested indivdulas and representatives of organizations must submit a letter of intent to present comments and three (3) typewritten copies of the presentation, along with a brief description of the organization represented, to the attention of Dr. Geoffrey Cheung, Office of Alternative Medicine, NIH, 31 Center Drive, MSC 2182, Building 31, Room 5B37, Bethesda, MD 20892, (301) 594–2013, FAX: (301) 594–6757. Letters of intent and copies of presentations must be received no later than 5:00 p.m. on Friday September 18.

Any person attending the meeting who does not request an opportunity to speak in advance of the meeting may be considered for oral presentation, if time permits, and at the discretion of the Chairperson.

Ms. Odessa Colvin, Program Assistant, Office of Alternative Medicine, 31 Center Drive, MSC 2182, Building 31, Room 5B37, Bethesda, MD 20892, (301) 594–2013, will provide a summary of the meeting and a roster of Council members as well as substantive program information. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Colvin no later than September 17, 1998.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meeting timing limitations imposed by the review and funding cycle.

Dated: September 4, 1998.

Ms. Anna Snouffer,

Acting Committee Management Officer, NIH.

[FR Doc. 98–24649 Filed 9–14–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(a)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Research Resources Special Emphasis Panel General Clinical Research Centers Committee

Date: November 16–18, 1998

Time: November 16, 1998, 2:00 PM to Adjournment

Agenda: To review and evaluate grant applications

Place: Johns Hopkins University, Ross Building, Room G007, 720 Rutland Avenue, Baltimore, MD 21205

Contact Person: John J. Ryan, PhD, Scientific Review Administrator, Office of Review, National Center For Research Resources, 6705 Rockledge Drive, MSC 7965,